Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: the ADVANCE trial by Ohkuma, Toshiaki et al.
 1 
 
 
 
 
 
 
 
 
 
 
 
 
Online-Only Supplemental Material
 2 
Supplemental Table 1. Sensitivity analysis; Discrimination and reclassification statistics (95% CIs) for 5-year risk of heart failure after addition of biomarkers to a 
model containing clinical risk factors after excluding patients with past history of hospitalization for heart failure 
 
   NRI 
C-statistic IDI Relative IDI (%) Continuous Categorical† 
Base model* 0.8007 (0.7585, 0.8430)     
Base model plus IL-6 0.8098 (0.7690, 0.8506) 0.015 (0.0005, 0.030) 5.39 (0.17, 1.49) 0.383 (0.176, 0.567) 0.013 (-0.067, 0.078) 
 P = 0.11 P = 0.04  P <0.001 P = 0.48 
Base model plus hs-CRP 0.8125 (0.7713, 0.8538) 0.028 (0.011, 0.048) 9.90 (3.82, 17.05) 0.264 (0.074, 46.4) 0.042 (-0.025, 0.114) 
 P = 0.17 P <0.001  P = 0.01 P = 0.23 
Base model plus hs-cTnT 0.8092 (0.7682, 0.8501) 0.010 (-0.004, 0.023) 3.68 (-1.20, 8.29) 0.427 (0.240, 0.606) 0.013 (-0.087, 0.110) 
 P = 0.29 P = 0.15  P <0.001 P = 0.34 
Base model plus NT-proBNP 0.8747 (0.8441, 0.9052) 0.099 (0.056, 0.145) 35.1 (18.8, 52.1) 0.783 (0.615, 0.949) 0.234 (0.117, 0.343) 
 P <0.001 P <0.001  P <0.001 P <0.001 
      
Base model plus IL-6, hs-CRP, and 
hs-cTnT 
0.8231 (0.7834, 0.8628)     
Addition of NT-proBNP 
to base model plus IL-6, 
hs-CRP, and hs-cTnT 
0.8768 （0.8462, 0.9074） 0.086 (0.044, 0.130) 26.1 (13.4, 40.3) 0.661 (0.491, 0.834) 0.209 (0.105, 0.316) 
P <0.001 P <0.001  P <0.001 P <0.001 
      
Base model plus NT-proBNP 0.8747 (0.8441, 0.9052)     
Addition of IL-6, hs-CRP, and 
hs-cTnT 
to base model plus NT-proBNP  
0.8768 （0.8462, 0.9074） 0.035 (0.016, 0.056) 9.14 (4.22, 14.69) 0.342 (0.117, 0.526) 0.007 (-0.055, 0.064) 
P = 0.70 P <0.001  P <0.001 P = 0.47 
Results were derived from the random subcohort (n = 2,871). 
Biomarkers were log transformed. 
* Base model included the same variables in Table 2 (see caption for Table 2), except for history of hospitalization for heart failure. 
† Using cutoff points of 5% and 10% 5-year risk. 
Abbreviations: IDI, integrated discrimination improvement; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; 
IL-6, interleukin-6; NRI, net reclassification improvement; NT-proBNP, N-terminal pro-B-type natriuretic peptide. 
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Supplemental Table 2. Sensitivity analysis; Discrimination and reclassification statistics (95% CIs) for 5-year risk of heart failure after addition of biomarkers to a 
model containing clinical risk factors after excluding patients with NT-proBNP levels >400 pg/mL 
 
   NRI 
C-statistic IDI Relative IDI (%) Continuous Categorical† 
Base model* 0.8215 (0.7674, 0.8755)     
Base model plus IL-6 0.8252 (0.7714, 0.8791) 0.001 (-0.014, 0.018) 0.42 (-4.65, 6.20) 0.215 (-0.051, 0.492) -0.001 (-0.077, 0.060) 
 P = 0.44 P = 0.23  P = 0.12 P = 0.77 
Base model plus hs-CRP 0.8226 (0.7696, 0.8756) 0.002 (-0.010, 0.012) 0.59 (-3.08, 4.22) 0.131 (-0.131, 0.402) -0.014 (-0.098, 0.062) 
 P = 0.90 P = 0.51  P = 0.33 P = 0.75 
Base model plus hs-cTnT 0.8223 (0.7682, 0.8764) 0.004 (-0.005, 0.015) 1.38 (-1.87, 4.92) 0.199 (-0.057, 0.463) 0.015 (-0.062, 0.092) 
 P = 0.63 P = 0.39  P = 0.12 P = 0.58 
Base model plus NT-proBNP 0.8640 (0.8162, 0.9119) 0.042 (0.009, 0.079) 15.0 (3.31, 28.0) 0.503 (0.268, 0.740) 0.194 (0.082, 0.315) 
 P = 0.009 P = 0.02  P <0.001 P = 0.002 
      
Base model plus IL-6, hs-CRP, and 
hs-cTnT 
0.8264 (0.7737, 0.8791)     
Addition of NT-proBNP 
to base model plus IL-6, 
hs-CRP, and hs-cTnT 
0.8647 （0.8171, 0.9123） 0.036 (0.007, 0.070) 12.6 (2.10, 24.8) 0.400 (0.145, 0.651) 0.231 (0.109, 0.373) 
P = 0.01 P = 0.02  P = 0.002 P = 0.002 
      
Base model plus NT-proBNP 0.8640 (0.8162, 0.9119)     
Addition of IL-6, hs-CRP, and 
hs-cTnT 
to base model plus NT-proBNP  
0.8647 （0.8171, 0.9123） 0.0002 (-0.009, 
0.010) 
0.06 (-2.91, 3.01) 0.151 (-0.128, 0.425) 0.049 (-0.022, 0.131) 
P = 0.88 P = 0.10  P = 0.26 P = 0.19 
Results were derived from the random subcohort (n = 2,643). 
Biomarkers were log transformed. 
* Base model included the same variables in Table 2 (see caption for Table 2). 
† Using cutoff points of 5% and 10% 5-year risk. 
Abbreviations: IDI, integrated discrimination improvement; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; 
IL-6, interleukin-6; NRI, net reclassification improvement; NT-proBNP, N-terminal pro-B-type natriuretic peptide. 
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Figure legends 
 
Supplemental Figure 1: The case-cohort study design and data availability. 
 
Supplemental Figure 2: Sensitivity analysis; Adjusted hazard ratios and 95% CIs 
for heart failure according to a one standard deviation increment in biomarkers 
after excluding patients with past history of hospitalization for heart faileure. 
Abbreviations: ECG, electrocardiogram; HR, hazard ratio; hs-CRP, high-sensitivity C-
reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; IL-6, interleukin-6; NT-
proBNP, N-terminal pro-B-type natriuretic peptide; SD, standard deviation. 
Hazard ratios were adjusted for the variables in Figure 2 (see caption for Figure 2). 
Model 2 was adjusted for the variables except for history of hospitalization for heart 
failure. 
 
Supplemental Figure 3: Sensitivity analysis; Adjusted hazard ratios and 95% CIs 
for heart failure according to a one standard deviation increment in biomarkers 
after excluding patients with NT-proBNP levels >400 pg/mL. 
Abbreviations: ECG, electrocardiogram; HR, hazard ratio; hs-CRP, high-sensitivity C-
reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; IL-6, interleukin-6; NT-
proBNP, N-terminal pro-B-type natriuretic peptide; SD, standard deviation. 
Hazard ratios were adjusted for the variables in Figure 2 (see caption for Figure 2). 
 
Supplemental Figure 4: Adjusted hazard ratios and 95% CIs for heart failure 
according to a one standard deviation increment in NT-proBNP, stratified by sex, 
age, duration of diabetes, history of myocardial infarction, and a history of 
hospitalization for heart failure. 
Abbreviations: DM, diabetes mellitus; HF, heart failure; MI, myocardial infarction; NT-
proBNP, N-terminal pro-B-type natriuretic peptide. 
Hazard ratios were adjusted for the variables in model 2 (see caption for Figure 2), 
except for myocardial infarction, where insulin was dropped from the model to allow 
convergence. 
 
 5 
 
 6 
 7 
 
 8 
 
